PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Jan 13, 2021

PTC Therapeutics根据纳斯达克上市规则5635报告奖励金-2021年1月13日

2021-01-14 18:19:31 BioSpace

本文共816个字,阅读需3分钟

PTC Therapeutics, Inc. today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units , each representing the right to receive one share of its common stock upon vesting, to 10 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on January 6, 2021 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). All stock option awards have an exercise price of $66.49 per share, the closing price of PTC's common stock on January 6, 2021, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates. ABOUT PTC THERAPEUTICS, INC. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. For more information please contact: Media & Investors: Jane Baj +1 (908) 912-9167 jbaj@ptcbio.com View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301207727.html SOURCE PTC Therapeutics, Inc. Company Codes: NASDAQ-NMS:PTCT
PTC Therapeutics,Inc.今天宣布,它于2021年1月6日批准了非法定股票期权,以购买总计13,465股普通股和4,665股限制性股票单位,每个单位代表在授予10名新员工时获得一股普通股的权利。这些赔偿金是根据纳斯达克奖励补助金例外规定发放的,作为新雇员就业补偿的一个组成部分。 奖励津贴已于2021年1月6日获PTC薪酬委员会批准,并根据纳斯达克上市规则5635(c)(4)作为每位员工接受本公司雇用的奖励材料。 所有股票期权奖励的行权价格为每股66.49,即授予日2021年1月6日PTC普通股的收盘价。每个股票期权的期限为10年,并在四年内归属,在适用的雇员新雇用日期的第一周年归属原始股份数量的25%,在其后每个三个月期间结束时归属原始股份数量的6.25%,直至完全归属,但须视雇员在适用的归属日期内继续为公司服务而定。在适用的雇员新雇用日的每一个年度周年纪念日,RSUs将在四年时间内按原归属股份数量的25%归属,直至全部归属,但须视雇员在适用的归属日期内继续为公司服务而定。 PTC治疗公司简介。 PTC是一家科学驱动的全球生物制药公司,专注于发现,开发和商业化临床上有区别的药物,为罕见疾病患者提供益处。PTC在全球范围内商业化产品的能力是推动对强大的变革性药物管道进行投资的基础,也是我们为那些医疗需求未得到满足的患者提供一流治疗的使命。 欲了解更多信息,请联系: 媒体和投资者: 简·巴吉 +1(908)912-9167 jbaj@ptcbio.com 查看原文内容:http://www.prnewswire.com/news-releases/ptc-therapeutics-reports-indument-grants-under-nasdaq-listing-rule-5635c4-301207727.html 源PTC治疗公司。 公司代码:NASDAQ-NMS:PTCT

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文